Celyad Faces “Go-or-No-Go” Decisions on Lead CAR-T Candidates

0

Chimeric antigen receptor T-cell therapy developer Celyad says it expects to make some go-or-no-go decisions about its lead CAR-T candidates now in Phase I/II trials, based on data readouts expected by year’s end . . .

Get GEN Edge Today!